Edition:
India

Sino Biopharmaceutical Ltd (1177.HK)

1177.HK on Hong Kong Stock

12.28HKD
16 Jul 2018
Change (% chg)

HK$0.08 (+0.66%)
Prev Close
HK$12.20
Open
HK$12.20
Day's High
HK$12.46
Day's Low
HK$12.14
Volume
23,143,842
Avg. Vol
46,240,932
52-wk High
HK$13.93
52-wk Low
HK$4.33

Latest Key Developments (Source: Significant Developments)

Sino Biopharmaceutical Says Injection Obtained Drug Registration Approval By National Drug Administration
Wednesday, 27 Jun 2018 

June 27 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::DOCETAXEL INJECTION HAS OBTAINED APPROVAL FOR DRUG REGISTRATION BY NATIONAL DRUG ADMINISTRATION OF PEOPLE'S REPUBLIC OF CHINA.  Full Article

Sino Biopharmaceutical Says Trustee Purchased 5.1 Mln Shares Pursuant To Restricted Share Award Scheme
Friday, 1 Jun 2018 

June 1 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::FROM 23 MAY TO 1 JUNE , TRUSTEE PURCHASED 5.1 MILLION SHARES FROM MARKET TO HOLD ON TRUST FOR PARTICIPANTS FOR HK$97.4 MILLION.  Full Article

Sino Biopharmaceutical Posts Qtrly Net Profit Of RMB771.1 Mln
Friday, 18 May 2018 

May 18 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::QTRLY REVENUE WAS ABOUT RMB4,652.61 MILLION, UP 20.4%.QTRLY NET PROFIT RMB771.1 MILLION VERSUS RMB 579 MILLION.DECLARED PAYMENT OF A FIRST QUARTERLY DIVIDEND OF HK2 CENTS PER SHARE.  Full Article

Sino Biopharmaceutical Says Compound Sodium Acetate Ringer's Injection Gets Drug Registration Approvals
Wednesday, 2 May 2018 

May 2 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::COMPOUND SODIUM ACETATE RINGER'S INJECTION OBTAINS TWO APPROVALS FOR DRUG REGISTRATION BY CHINA FOOD AND DRUG ADMINISTRATION.  Full Article

Sino Biopharmaceutical Announces Proposed Bonus Issue Of Shares
Tuesday, 17 Apr 2018 

April 17 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::RECOMMENDS A BONUS ISSUE OF SHARES ON BASIS OF ONE BONUS SHARE FOR EVERY TWO EXISTING SHARES HELD BY QUALIFYING SHAREHOLDERS.EXPECTED THAT A TOTAL OF 4.21 BILLION BONUS SHARES WOULD BE ALLOTTED AND ISSUED.  Full Article

Sino Biopharmaceutical Co Announces Acquisition of Sino Biopharm Beijing​ & Super Demand
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::CO TO ACQUIRE SINO BIOPHARM BEIJING​,WHICH OWNS 33.6% OF BEIJING TIDE, BY ISSUING 723.3 MILLION SHARES AT HK$12.73 PER ISSUE SHARE.‍FRANCE INVESTMENT (CHINA 1) GROUP TO SELL 52 PERCENT STAKE IN SUPER DEMAND FOR HK$3.69 BILLION TO CO ​.  Full Article

Sino Biopharmaceutical Product Granted Drug Registration Approval By State FDA Of China​
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::"TENOFOVIR DISOPROXIL FUMARATE TABLET" GRANTED DRUG REGISTRATION APPROVAL BY STATE FOOD AND DRUG ADMINISTRATION OF CHINA​.‍TENOFOVIR DISOPROXIL FUMARATE GRANTED APPROVAL FOR TREATMENT OF CHRONIC HEPATITIS B​.  Full Article

Sino Biopharmaceutical posts 9-month ‍net profit attributable of RMB1.80​ bln
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK> ::9-month ‍revenue RMB11,446.73 million, up 9.5​ percent.‍Declared payment of a third quarterly dividend of HK2 cents per share for three months ended 30 Sept​.9-month net profit attributable to owners RMB1.80​ billion versus RMB1.30 billion.  Full Article

Sino biopharmaceutical enters into a facility agreement
Wednesday, 28 Sep 2016 

Sino Biopharmaceutical Ltd <1177.HK> : Loan facility in an aggregate principal amount of US$300 million . Company, as borrower, entered into a facility agreement with original lenders . Original lenders have agreed to make available to company a dual tranche three-year term loan facility .Amount borrowed under loan facility will be used by company for refinancing of existing loans owed by company.  Full Article

Sino Biopharmaceutical says there was fire in treatment plant at Lianyungang<1177.HK>
Thursday, 1 Sep 2016 

Sino Biopharmaceutical Ltd <1177.HK>: On 27 August 2016, there was a fire in an used waste solvent treatment plant at Lianyungang, PRC . Accident did not extend to production plants and the subsidiary has resumed full production . Expects the incident does not have any material impact on the group's general operation, financial position and cash flows. . There were damages to certain properties and facilities of the subsidiary .  Full Article